Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for PRADAXA
- A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
- A Study to Learn How the Study Drug Elinzanetant (BAY 3427080) Affects the Way the Drug Dabigatran Moves Into, Through and Out of the Body in Healthy Male and Female Participants
- Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI
- A Single Dose Bioequivalence Study of WD-1602 Versus Pradaxa® in Healthy Subjects Under Fed Condition
- A Study of the Effect of Quizartinib on the Pharmacokinetics of the P-gp Substrate Dabigatran Etexilate in Healthy Participants
- A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers
- Dabigatran for Mitral Stenosis Atrial Fibrillation
- DOAC Versus VKA After Cardiac Surgery
- PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation
- MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
- Treating Acute Pancreatitis With Dabigatran, a Pilot Study
- RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD
- A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.
- Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).
- Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers
- Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
- D-dimer to Guide Anticoagulation Therapy in Patients With Atrial Fibrillation
- A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism
- Start or STop Anticoagulants Randomised Trial (SoSTART)
- Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan
- Bioequivalence of Tablet Formulation of Dabigatran Etexilate Compared to Commercial Capsule Formulation Following Oral Administration in Healthy Male Subjects
- Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation
- Dabigatran Versus Conventional Treatment for Prevention of Silent Cerebral Infarct in Atrial Fibrillation Associated With Valvular Disease
- Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism undergoIng Endovascular Mechanical Fragmentation and Thrombolytic Therapy
- Dabigatran as an Alternative Anticoagulant in Patients With Left Ventricular Assist Device (LVAD)
- Patient Convenience Study- NIS RELATE
- Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer
- Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Low Molecular Weight Heparin for 72 Hours Followed by Dabigatran for Acute Intermediate-Risk Pulmonary Embolism.
- Left Atrial Thrombus Reduction - Effect of Dabigatran Versus Phenprocoumon
- Pleotropic Effect of New Oral Anticoagulants
- Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity
- Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
- Canadian Pradaxa Acute Stroke Safety Study
- Effects of Low Molecular Weight Heparin Versus Dabigatran on Platelet Aggregation in Patients With Stable Coronary Artery Disease
- Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran
- Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)
- Management of Major Bleeding Events in Atrial Fibrillation Patients Using Pradaxa
- Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism
- Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
- Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
- SPARK: Safety Study of Pradaxa in Atrial Fibrillation Patients by Regulatory Requirement of Korea
- Rhythm Evaluation for AntiCoagulaTion With COntinuous Monitoring
- Strategy of Continued Versus Interrupted Novel Oral Anti-coagulant at Time of Device Surgery in Patients With Moderate to High Risk of Arterial Thromboembolic Events
- Management of Myocardial Injury After Noncardiac Surgery Trial
- Early Versus Late DC-cardioversion of Persistent Atrial Fibrillation. Effect on Atrial Remodeling,Inflammatory and Neurohumoral Markers and Recurrence of Atrial Fibrillation
- Dabigatran's Effect on Changes in Atrial Fibrosis in Patients With Atrial Fibrillation
- A Prospective, Open Label Study Evaluating Two Management Strategies on Gastrointestinal Symptoms in Patients Newly on Treatment With Pradaxa for the Prevention of Stroke and Systemic Embolism With Non-valvular Atrial Fibrillation
- Investigation Drug-drug Interaction Between Dabigatran and Clarithromycin
- Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
- Impact of Dabigatran and Phenprocoumon on ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation
- Pharmacokinetics of Dabigatran Etexilate (Pradaxa®) During Haemodialysis
- Study in Healthy Volunteers of the Reversion by Haemostatic Drugs of the Anticoagulant Effect of New Anti-thrombotics
- Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
- Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
Clinical trials list
click for details